Show simple item record

dc.contributor.authorVitry, Agnes
dc.contributor.authorNguyen, Tuan
dc.contributor.authorEntwistle, Vikki
dc.contributor.authorRoughead, Elizabeth
dc.date.accessioned2015-10-21T11:32:02Z
dc.date.available2015-10-21T11:32:02Z
dc.date.issued2015-10-19
dc.identifier.citationVitry , A , Nguyen , T , Entwistle , V & Roughead , E 2015 , ' Regulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case study ' , Journal of Pharmaceutical Policy and Practice , vol. 8 , 25 . https://doi.org/10.1186/s40545-015-0046-2en
dc.identifier.issn2052-3211
dc.identifier.otherPURE: 56969078
dc.identifier.otherPURE UUID: a2b3ae59-9b6d-4912-bc0e-1a6ccbcb74ba
dc.identifier.otherScopus: 84983167630
dc.identifier.urihttp://hdl.handle.net/2164/5095
dc.descriptionAcknowledgements Professor Elizabeth Roughead is funded by a Future Fellowship from the Australian Research Council. The views expressed are those of the authors, the sponsor had no role in the preparation of the manuscript.en
dc.format.extent11en
dc.language.isoeng
dc.relation.ispartofJournal of Pharmaceutical Policy and Practiceen
dc.rights© 2015 Vitry et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectpharmaceutical policyen
dc.subjectmanaged entry agreementen
dc.subjectmedicine subsidizationen
dc.subjectcoverage with evidence developmenten
dc.subjectRS Pharmacy and materia medicaen
dc.subject.lccRSen
dc.titleRegulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen, Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1186/s40545-015-0046-2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record